The American Medical Association released its "Health Insurer Code of Conduct Principles," which defines 10 standards AMA believes will ensure consistent corporate practices.
NATIONAL REPORTS-The American Medical Assn. (AMA) released its "Health Insurer Code of Conduct Principles," which defines 10 standards AMA believes will ensure consistent corporate practices.
The organization sent letters to the chief executive officers of major insurers, including the Blue Cross Blue Shield Assn. Letters ask insurers for their "commitment to full transparency and accountability with respect to all of their clinical and administrative processes."
Issues addressed in the guidelines include: cancellation of coverage, medical spending, access to care, fair contracting, patient confidentiality, and administrative simplification. The standards are endorsed by 68 state and specialty medical societies, according to AMA.
"The code echoes much of the requirements set forth in the PPACA law," says Lisa G. Han, partner, Squire, Sanders & Dempsey. "There are opportunities for greater collaboration between payers and providers under the healthcare reform law."
Han says that the medical community has a right to identify potential issues in the insurance industry, however most insurers already follow the code's specifications.
According to Kaiser Permanente Ohio spokesperson Renee DeLuca, her organization is aware of the code and has updated policies to reflect it.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More